Published in
Public Library of Science, PLoS ONE, 12(9), p. e115387, 2014
DOI: 10.1371/journal.pone.0115387
Links
- Public Library of Science
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net] | PDF
- [arts.units.it] | PDF
- [www.plosone.org] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net]
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model
,
Germana Meroni,
Chiara Agnoletto,
Giorgio Zauli,
Paola Secchiero
Full text: Download
Abstract
Ovalbumin (OVA)-sensitized BALB/c mice were i.n. instilled with recombinant TNF-related apoptosis inducing ligand (TRAIL) 24 hours before OVA challenge. The total number of leukocytes and the levels of the chemokine CXCL-1/KC significantly increased in the bronchoalveolar lavage (BAL) fluids of allergic animals with respect to control littermates, but not in the BAL of mice i.n. pretreated with recombinant TRAIL before OVA challenge. In particular, TRAIL pretreatment significantly reduced the BAL percentage of both eosinophils and neutrophils. On the other hand, when TRAIL was administrated simultaneously to OVA challenge its effect on BAL infiltration was attenuated. Overall, the results show that the i.n. pretreatment with TRAIL down-modulated allergic airway inflammation.